As awareness and accessibility of TMS therapy increase ... has granted clearance for its NeuroStar Advanced Therapy system as an adjunct treatment for major depressive disorder (MDD) in ...
GlobalData on MSN11mon
Neuronetics’s NeuroStar wins FDA clearance for adolescents with depressionThe TMS market is becoming more crowded ... Adults are eligible for neuromodulation devices such as Magnus Medical’s SAINT ...
Operating expenses during the fourth quarter of 2024 were $25.8 million, an increase of $5.6 million, or 28%, compared to $20.2 million in the fourth quarter of 2023, mainly attributable to ...
In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United ...
12d
Neuronetics Inc (STIM) reports an 11% revenue increase, driven by strategic acquisitions and market expansion, despite ...
In addition to selling the NeuroStar system and associated treatment sessions to customers, Greenbrook TMS Inc. (“Greenbrook”) operates treatment centers across the United States, offering ...
The company shipped 46 NeuroStar systems, contributing $3.8 million in revenue. Neuronetics completed the acquisition of Greenbrook TMS, enhancing its treatment network. The stock price increased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results